The U.S. Court of Appeals for the D.C. Circuit recently ruled that pharmaceutical manufacturers, including Novartis Pharmaceuticals Corporation, cannot implement new pricing models for drug sales under the 340B Program without prior approval from the Secretary of Health and Human Services (HHS). This decision affects how drug manufacturers sell their products to healthcare providers that serve low-income patients, impacting the availability of affordable medications.
The case, Novartis Pharmaceuticals Corporation v. Robert F. Kennedy, Jr. (Docket No. 25-5177), arose from a dispute over the implementation of rebate models proposed by Novartis and three other manufacturers. These companies sought to change how they provide discounts on drugs sold to covered entities, which include hospitals and clinics that serve low-income populations.
The 340B Program, established in 1992, requires participating drug manufacturers to sell certain medications at reduced prices to eligible healthcare providers. Historically, manufacturers complied by offering upfront discounts. However, in 2024, Novartis and three other companies proposed to switch to a rebate model, where providers would pay full price initially and then receive a refund after dispensing the drugs. The Secretary of HHS, however, stated that such a model could not proceed without his approval, leading to the manufacturers' lawsuit.
The manufacturers argued that the statute allows them to implement their proposed rebate models unless the Secretary explicitly disapproves them. However, the D.C. Circuit Court disagreed, affirming the district court's ruling that the Secretary must approve any new pricing mechanisms before they can be implemented. The court stated, “the Secretary shall enter into an agreement with each manufacturer… under which the amount required to be paid… does not exceed… the ‘ceiling price.’” This ruling reinforces the Secretary's control over how drug pricing is structured under the 340B Program.
The court's opinion, authored by Circuit Judge Garcia, emphasized that the statutory text requires the Secretary to provide for any rebate mechanism before manufacturers can implement one. “The Secretary will ‘supply’ or ‘make… available’ the relevant mechanisms,” the opinion noted, indicating a clear preapproval requirement. The ruling also highlighted that the Secretary has not authorized any rebate model that encompasses the manufacturers' proposals, thus validating the Secretary's request for further information before any changes could be made.
This ruling has significant implications for both drug manufacturers and healthcare providers. It reinforces the Secretary's authority to regulate drug pricing mechanisms under the 340B Program, ensuring that any changes are carefully considered and approved before implementation. The decision could discourage manufacturers from attempting to unilaterally change pricing structures, as they must now navigate the approval process with HHS.
Going forward, this ruling may set a precedent for how drug pricing is managed under federal programs. It emphasizes the importance of regulatory oversight in ensuring that drug prices remain affordable for low-income patients. The decision also indicates that manufacturers must engage with the Secretary and provide sufficient justification for any proposed changes to pricing models.
As for next steps, the manufacturers have the option to appeal the ruling, although details about whether they will pursue this route were not provided in the court filing. Additionally, there may be related cases pending as the Secretary continues to evaluate the proposals submitted by the manufacturers. The ongoing review process means that the future of rebate models in the 340B Program remains uncertain, pending further developments from HHS.